Number of partners
President and CEO
Chief Scientific Officer
Founder and Managing Partner, Proteus Venture Partners
Turning the promise of regenerative medicine into reality
Regenerative medicine (RM)-based therapies hold enormous potential to repair, regenerate or replace diseased cells, tissues and organs. But many of these potentially life-changing treatments never reach patients because they are not successfully moved from the lab to the clinic. Fortunately, Canada is a global hotbed for stem cell research, bioengineering and biomaterials. Building on this expertise, stem cell scientists and bioengineers across six RM centres in Ontario supported the creation of a new commercialization centre that would bridge the gap between academia and industry and enable promising technologies to reach the market.
How CCRM is seizing the opportunity
The Centre for Commercialization of Regenerative Medicine (CCRM) overcomes two major bottlenecks in RM commercialization: a dearth of early stage capital and access to centralized research infrastructure. CCRM provides small- and medium-sized enterprises, large multinationals and emerging biotechnology companies with a single entry point for accessing Canada-wide RM expertise and infrastructure. CCRM’s industry consortium of nearly 50 Canadian and international RM companies can also access a fully resourced, 550 square metre development facility designed for bioprocess optimization. CCRM is capitalizing on its extensive pipeline of ideas to bundle promising technologies into 10 new companies that are strategic and leverage expertise, funding and excellent science.
Among the results
- CCRM’s partnership with the CellCAN Regenerative Medicine and Cell Therapy Network is harmonizing the operations of an 1,850 square metre state-of-the-art good manufacturing practice (GMP) cell manufacturing facility that is being built to support academic and private sector partners, and other existing facilities across Canada. The facility will be housed at CCRM and operated on behalf of the University Health Network.
- Thanks to investments from CCRM, two Canadian companies launched in 2016: AVROBIO, a clinical-stage biotechnology company accelerating the development of two novel cell and gene therapies for patients with acute myeloid leukemia and Fabry disease, and Actium (now KisoJi Biotechnology Inc.), a cancer stem cell company whose platform has the potential to identify novel cancer stem cell molecular targets.
- With funding from GE Healthcare and the Federal Economic Development Agency for Southern Ontario, CCRM is building a new centre for advanced therapeutic cell technologies in Toronto. The centre will provide cell therapy companies with facilities and expertise to establish manufacturing processes to produce the large cell numbers required for clinical and commercial use.
- ExCellThera, a spin-off company launched by CCRM and the Institute for Research in Immunology and Cancer - Commercialization of Research, in partnership with Hopital Maisonneuve-Rosement, began its first clinical trial in 2016. The product represents a new therapeutic option for patients who require stem cell transplantation to treat acute myeloid leukemia and other malignant blood disorders, and who lack a traditional donor.
Connect with CCRM